Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Having suffered considerable setbacks in launching its core pipeline drugs, Takeda Pharmaceutical will focus on expanding sales growth of existing products, including the gastronomic treatment Kapidex (dexlansoprazole) and gout medication Uloric (febuxostat) that were approved by U.S. FDA in early 2009, the company said in its earnings report and related documents May 11
You may also be interested in...
Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM
TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma
Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM
TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma
Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential
Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore